Phellodendron amurense (Amur cork tree) inner bark is a dietary supplement used for blood sugar, cholesterol, stress, weight, and joint comfort. No controlled trial has tested oral bark alone; positive human studies use manufacturer-funded herbal blends with inconsistent results. Because oral bark blocks liver enzymes and cellular pumps that clear medications and risks heart-rhythm, potassium, kidney, and liver strain, standalone use remains unproven for longevity. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting plasma glucose | 70–99 mg/dL (standard reference range) | Efficacy marker: expected to decrease in overweight or insulin-resistant users (10–12 hour overnight fast; paired with HbA1c at 12 weeks). |
| LDL-C & fasting triglycerides | LDL-C < 100 mg/dL; triglycerides < 150 mg/dL (standard reference range) | Efficacy marker: both decreased over 8 weeks in NP 06-1 trials (10–12 hour fast at baseline and week 8). |
| High-sensitivity CRP | < 3.0 mg/L (standard reference range) | Efficacy marker: decreased by 49% in overweight osteoarthritis patients on NP 06-1. |
| Diurnal salivary cortisol | No established target; percent reduction from individual baseline | Efficacy marker: composite morning, noon, and evening salivary cortisol fell 18% on Relora (baseline and week 4). |
| Serum ALT, AST & total bilirubin | ALT 7–56 U/L; AST 8–33 U/L; bilirubin 0.1–1.2 mg/dL (standard reference range) | Safety check: detects limonoid hepatotoxicity or berberine bilirubin displacement (discontinued if ALT/AST > 3× upper limit of normal or bilirubin rises). |
| Serum creatinine & eGFR | Creatinine 0.6–1.3 mg/dL; eGFR ≥ 60 mL/min/1.73 m² (standard reference range) | Safety check: monitors for high-dose renal tubular stress seen in rat studies (baseline, week 4, and week 8). |
| Serum potassium & 12-lead electrocardiogram (QTc) | Potassium 3.5–5.0 mmol/L; QTc ≤ 450 ms in men, ≤ 470 ms in women (standard reference range) | Safety check: high-dose Nexrutine caused Grade 1 QTc prolongation (14.3%) and Grade 3 hypokalemia (4.8%) (baseline and week 4 at ≥ 1,500 mg/day or with QT-prolonging drugs). |
Cadence: Baseline, week 4 (potassium, QTc, and liver/kidney safety markers), weeks 8–12 (lipid, glucose, CRP, or salivary cortisol efficacy response), and every 3–6 months during extended cyclical use.